Success Stories: Start-Ups

Cx Precision Medicine Logo

Cx Precision Medicine, Inc. looks at blood based bio-markers to identify therapeutics to treat Alzheimer’s Disease. Cx’s patent portfolio includes technology for a low cost blood test to effectively screen out Alzheimer’s Disease in older adults and to identify a risk of Alzheimer’s Disease that would require in depth medical evaluation.
Founded in 2016

Endophys logo

Endophys Holdings, LLC is a Dallas-based, privately held medical device company that develops pressure sensing access systems which improve the safety and outcome in critical procedures in cath/angiography labs by providing immediate, continuous, and accurate endovascular physiology. The Company is currently developing a version of the pressure sensing access sheath for use in stroke procedures and expects to have it commercially available in 2017.
Founded in 2014

Exonics Therapeutics Logo

Exonics Therapeutics, located in Dallas, Texas, is a biotechnology company focused on developing gene editing technologies like CRISPR/Cas9 to correct genetic mutations resulting in neuromuscular diseases such as Duchenne muscular dystrophy. While the company's initial focus is on Duchenne, it looks forward to advancing its gene editing platform to additional pediatric indications with significant unmet medical need.
Founded in 2017

Macrogenics Logo

Macrogenics, Inc. is focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infections diseases.
Founded in 2000

miRagen logo

miRagen Therapeutics, Inc. is a clinical stage biopharmaceutical company discovering and developing innovative RNA-targeting therapies to improve human health, with a specific focus on microRNAs and disease areas of high unmet medical needs.
Founded in 2007

OmeicosTherapeutics Logo

Omeicos Therapeutics develops metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular, and other diseases. Epoxyeicosanoids, as a newly described class of bioactive lipid mediators, activate cell type-specific endogenous pathways that promote organ and tissue protection. Omeicos’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts.
Founded in 2013

Peloton Therapeutics logo

Peloton Therapeutics, Inc. is an oncology drug discovery and development company focused on advancing first-in-class small molecule therapies that provide patients suffering from life-threatening diseases with new therapeutic options.
Founded in 2011

Peregrine logo

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products. The company is working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer.
Founded in 1981

Reata Pharmaceuticals Logo

Reata Pharmaceuticals is a biopharmaceutical company based in Irving, Texas. Its mission is to develop novel therapeutics for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.
Founded in 2002

ReCode Therapeutics Logo

ReCode Therapeutics is a biopharmaceutical company developing first-in-class tRNA therapeutics for correction of nonsense mutations that account for approximately 10 percent of all genetic diseases, including cystic fibrosis, Duchenne Muscular Dystrophy, cancer, and others. ReCode Therapeutics’ rRNA therapeutics are enabled by a platform of unique and proprietary nanoparticle carriers for delivery of long RNAs including rRNA, mRNA and CRISPR RNAs.
Founded in 2016

Sienna Cancer Diagnostics Logo

Sienna Cancer Diagnostics is a biotechnology company based in Melbourne, Australia. Their focus is the development and commercialization of novel IVD tests that solve unmet clinical needs in the diagnosis or characterization of cancer. Sienna’s primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009.
Founded in 2007

Starr Frame logo

Starr Frame LLC is a privately held company that develops and markets innovative medical products that facilitate orthopaedic and other surgical procedures.
Founded in 2008